Novartis presents additional Zolgensma data in children with SMA
Novartis subsidiary AveXis has announced interim data for Zolgensma (onasemnogene abeparvovec-xioi) in children with spinal...
Read More...
Focus:
Europe
-
![Versantis raises funds to advance liver disease drugs]()
Versantis raises funds to advance liver disease drugs
Swiss biotech firm Versantis has completed a series B funding round to support the clinical...
Read More...
-
![]()
Marry Jane
Marry Jane (MJ) creates lifestyle products, cosmetics and tobacco substitutes with high-cannabidiol (CBD) / low-tetrahydrocannabinol...
Read More...
-
Oncoheroes signs cancer asset licensing deal with Boehringer
US-based biotech company Oncoheroes Biosciences has entered into a licensing agreement with Boehringer Ingelheim for...
Read More...
-
![Lundbeck signs $1.95bn deal to buy Alder BioPharmaceuticals]()
Lundbeck signs $1.95bn deal to buy Alder BioPharmaceuticals
Danish pharmaceutical company Lundbeck has signed a definitive agreement to acquire all outstanding shares of...
Read More...
-
![]()
FDA to review ranitidine after detecting cancer-causing contamination
The US Food and Drug Administration (FDA) has issued a statement regarding the safety of...
Read More...
-
Inotrem secures funds to develop septic shock treatment
Biotechnology company Inotrem has secured series B funding to develop immunotherapy candidates targeting septic shock...
Read More...
-
![Orkambi available in Scotland]()
Scotland reaches access agreement with Vertex for CF drug Orkambi
Vertex Pharmaceuticals has announced two of its cystic fibrosis (CF) drugs, Orkambi (lumacaftor-ivacaftor) and Symkevi...
Read More...
-
![gene therapy Genenta funding]()
Gene therapy biotech Genenta raises €13.2m in funding round
Milan-based clinical stage biotech Genenta Science has announced it has raised €13.2m at the closing...
Read More...
-
Genmab partners Tempus to identify new cancer targets
Danish biotechnology company Genmab has partnered with US-based technology firm Tempus to research and develop...
Read More...